Want to see TSE:BCT full AI Analyst Report?
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$3.68 - C$20.40
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$45.76M
Enterprise Value-C$1.60M
Total Cash (Recent Filing)C$22.80M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding8,699,787
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Net-cash, No-debt Balance SheetA net-cash, zero-debt capital structure with rising shareholders' equity provides durable financial flexibility for a clinical-stage biotech. It lowers insolvency and leverage risk, extending runway for R&D and permitting strategic partnering or staged financings without immediate debt pressure.
Pivotal Phase 3 Trial Progressing With Broad Site FootprintHaving an active pivotal Phase 3 with 80+ sites and new major centers joining materially improves trial enrollment capacity and regulatory credibility. Sustained, broad site participation reduces execution risk and is a structural step toward potential approval and commercialization.
Scalable Manufacturing Partnership With Fujifilm BiotechnologiesA CDMO agreement for cell therapy manufacturing establishes a durable operational capability for clinical and potential commercial supply. This reduces execution risk, supports regulatory submissions, and signals planning for scale if Bria-IMT advances to market.
Bears Say
Pre-revenue With Sustained Large Operating LossesZero revenue and recurring large operating losses are structural constraints for a clinical-stage biotech. Without product sales, the company must continually access capital; ongoing negative earnings signal a multi-period path to profitability contingent on clinical and regulatory success.
High And Worsening Cash BurnElevated, worsening cash outflows create persistent financing needs. High cash burn shortens runway and increases likelihood of dilutive capital raises or unfavorable financing, which can impair shareholder value and constrain investment in concurrent development programs.
Negative ROE And Prior Equity VolatilityDeeply negative ROE and past episodes of negative shareholders' equity reflect accumulated deficits and capital instability. This structural weakness raises funding risk, may limit strategic options, and indicates that future capital injections could be required to sustain operations.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$3.68 and its highest was C$20.40 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$45.76M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 95 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Jun 09, 2026. The company reported -C$1.354 earnings per share for the quarter, missing the consensus estimate of N/A by -C$1.354.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 8,699,787 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$1.354 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.728%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-147.92%
Trailing 12-Months
Asset Growth
56.90%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―